Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

Fighting the stigmatization of monkeypox patients

Posted on August 11th, 2022 by

When disease outbreaks occur, health experts are not only faced with the challenge of getting good information out to people – they also must battle misinformation. Rumors fly, people share bits and pieces of articles that they only skimmed, and social media posts full of bad science go viral. Sometimes, when the outbreak begins in a certain locality or hits a particular demographic really hard, they must also contend with the problem of stigmatization – which is now happening with the monkeypox outbreak.

(more…)

Preprints offer early insights into research

Posted on August 9th, 2022 by

To stay competitive in R&D, it is critical to keep abreast of all the latest findings and innovations. Preprints are offering a new way to remain ahead of the curve, allowing a look into new research prior to the peer-review process.

(more…)

Mobilizing against monkeypox

Posted on August 3rd, 2022 by

As the world continues to navigate Covid and its many strains, it would be an understatement to say that everyone is on high alert for other types of outbreaks. Monkeypox is now top of mind, as the disease – first identified in humans in 1970 and mostly found in rainforest areas in Central and West Africa – is now seeing its largest-ever outbreaks outside of the African continent.

(more…)

Reaxys User Day 2022: Researcher secrets in the spotlight

Posted on May 26th, 2022 by

In April, Elsevier hosted the first Reaxys User Day to learn from expert users and share best practices. Attendees were also updated on how the expert-curated chemistry database has dramatically upped its ability to streamline R&D. We spoke with senior director Ivan Krstic about how Reaxys is turning data into actionable insights to better understand the competitive landscape, design novel compounds, and generally accelerate synthetic chemistry. “Today is about sharing the amazing strides we’ve made,” says Ivan.

(more…)

  1. 1
  2. 2
  3. 3
  4. 93